drugset / Trial / NCT04803006
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
Timeline
- Start
- 2023-01-17
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.